86 related articles for article (PubMed ID: 25639891)
1. Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib.
Ho HK; Chan JC; Hardy KD; Chan EC
Drug Metab Rev; 2015 Feb; 47(1):21-8. PubMed ID: 25639891
[TBL] [Abstract][Full Text] [Related]
2. Interaction of lapatinib with cytochrome P450 3A5.
Chan EC; New LS; Chua TB; Yap CW; Ho HK; Nelson SD
Drug Metab Dispos; 2012 Jul; 40(7):1414-22. PubMed ID: 22511346
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
Teng WC; Oh JW; New LS; Wahlin MD; Nelson SD; Ho HK; Chan EC
Mol Pharmacol; 2010 Oct; 78(4):693-703. PubMed ID: 20624855
[TBL] [Abstract][Full Text] [Related]
4. Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.
Takakusa H; Wahlin MD; Zhao C; Hanson KL; New LS; Chan EC; Nelson SD
Drug Metab Dispos; 2011 Jun; 39(6):1022-30. PubMed ID: 21363997
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism.
Liu X; Lu Y; Guan X; Dong B; Chavan H; Wang J; Zhang Y; Krishnamurthy P; Li F
Biochem Pharmacol; 2015 Sep; 97(1):111-21. PubMed ID: 26212543
[TBL] [Abstract][Full Text] [Related]
6. Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate.
Barbara JE; Kazmi F; Parkinson A; Buckley DB
Drug Metab Dispos; 2013 May; 41(5):1012-22. PubMed ID: 23404373
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Benzbromarone.
Tang LWT; Verma RK; Fan H; Chan ECY
Mol Pharmacol; 2021 Apr; 99(4):266-276. PubMed ID: 33436520
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI).
Kamel A; Harriman S
Drug Discov Today Technol; 2013; 10(1):e177-89. PubMed ID: 24050247
[TBL] [Abstract][Full Text] [Related]
9. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
Ernest CS; Hall SD; Jones DR
J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of CYP3A.
Tang LWT; Fu J; Koh SK; Wu G; Zhou L; Chan ECY
Drug Metab Dispos; 2022 Jul; 50(7):931-941. PubMed ID: 35512804
[TBL] [Abstract][Full Text] [Related]
12. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
Li J; Zhao M; He P; Hidalgo M; Baker SD
Clin Cancer Res; 2007 Jun; 13(12):3731-7. PubMed ID: 17575239
[TBL] [Abstract][Full Text] [Related]
13. Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity.
Castellino S; O'Mara M; Koch K; Borts DJ; Bowers GD; MacLauchlin C
Drug Metab Dispos; 2012 Jan; 40(1):139-50. PubMed ID: 21965624
[TBL] [Abstract][Full Text] [Related]
14. In vitro assessment of the photo(geno)toxicity associated with Lapatinib, a Tyrosine Kinase inhibitor.
García-Lainez G; Vayá I; Marín MP; Miranda MA; Andreu I
Arch Toxicol; 2021 Jan; 95(1):169-178. PubMed ID: 32815004
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 inhibitory potential and RP-HPLC standardization of trikatu--a Rasayana from Indian Ayurveda.
Harwansh RK; Mukherjee K; Bhadra S; Kar A; Bahadur S; Mitra A; Mukherjee PK
J Ethnopharmacol; 2014 May; 153(3):674-81. PubMed ID: 24690772
[TBL] [Abstract][Full Text] [Related]
16. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors.
Filppula AM; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2014 Jul; 42(7):1202-9. PubMed ID: 24713129
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of CYP3A5 attenuates inducibility and activity of CYP3A4 in HepG2 cells.
Kuang Z; Huang Z; Li Y; Yang G; Liu M; Yuan H
Mol Med Rep; 2015 Apr; 11(4):2868-74. PubMed ID: 25434721
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-based inactivation of cytochromes by furan epoxide: unraveling the molecular mechanism.
Taxak N; Kalra S; Bharatam PV
Inorg Chem; 2013 Dec; 52(23):13496-508. PubMed ID: 24236636
[TBL] [Abstract][Full Text] [Related]
19. A novel in vitro approach for simultaneous evaluation of CYP3A4 inhibition and kinetic aqueous solubility.
Pérez J; Díaz C; Asensio F; Palafox A; Genilloud O; Vicente F
J Biomol Screen; 2015 Feb; 20(2):254-64. PubMed ID: 25296659
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome p450 architecture and cysteine nucleophile placement impact raloxifene-mediated mechanism-based inactivation.
VandenBrink BM; Davis JA; Pearson JT; Foti RS; Wienkers LC; Rock DA
Mol Pharmacol; 2012 Nov; 82(5):835-42. PubMed ID: 22859722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
